Filing Details

Accession Number:
0001562180-23-004067
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-05-11 13:53:12
Reporting Period:
2023-05-09
Accepted Time:
2023-05-11 13:53:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
105770 West Pharmaceutical Services Inc WST Surgical & Medical Instruments & Apparatus (3841) 231210010
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1336007 Mark Eric Green 530 Herman O. West Drive
Exton PA 19341
President & Ceo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-05-09 50,000 $57.38 178,574 No 4 M Direct
Common Stock Disposition 2023-05-09 14,157 $361.95 164,417 No 4 S Direct
Common Stock Disposition 2023-05-09 12,562 $362.93 151,855 No 4 S Direct
Common Stock Disposition 2023-05-09 12,648 $363.94 139,207 No 4 S Direct
Common Stock Disposition 2023-05-09 4,133 $364.76 135,074 No 4 S Direct
Common Stock Disposition 2023-05-09 500 $365.46 134,574 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2023-05-09 50,000 $0.00 50,000 $57.38
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
148,132 2025-04-24 No 4 M Direct
Footnotes
  1. The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in 2025, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 9/14/2022.
  2. This transaction was effective pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on 9/14/2022. The Rule 10b5-1 trading plan, which was structured to include several sale periods, was established as part of the Reporting Person's long-term strategy for asset diversification and financial, retirement, estate and tax planning activities over a period of time. In total, 50,000 options were exercised with 44,000 shares sold and 6,000 shares held by the reporting person.
  3. The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $361.42 to $362.41, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
  4. The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $362.42 to $363.41, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
  5. The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $363.42 to $364.41, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
  6. The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $364.425 to $365.295, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
  7. The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $365.43 to $365.48, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote.
  8. This option is fully vested.